We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How Abbott's Medical Devices Arm Acts as a Growth Catalyst
Read MoreHide Full Article
Key Takeaways
Abbott's Medical Devices growth is driven by electrophysiology, CGM and cardiovascular technologies.
Abbott sees 75-80 million potential CGM users globally versus about 15 million users today.
Abbott's cardiovascular pipeline includes TAVR, leadless pacing, mitral replacement and peripheral IVL.
Abbott Laboratories’ (ABT - Free Report) Medical Devices business continues to be one of the company’s strongest growth engines, supported by accelerating momentum in electrophysiology, continued adoption of cardiovascular technologies and the large long-term opportunity in continuous glucose monitoring (CGM).
Electrophysiology appears crucial to Abbott’s near-term growth acceleration. The company launched the next-generation Volt PFA catheter in the United States in May and expects to move from a limited release to a full commercial launch in the coming quarters.
Diabetes Care is another major pillar of Medical Devices growth. Abbott estimates that roughly 75-80 million people globally could realistically use CGM technology compared with only about 15 million users today. This wide penetration gap gives the company considerable runway even before factoring in future product innovation.
Abbott received CE Mark for Libre Duo in the second quarter and plans to begin its international rollout in fall 2026. Libre Duo is designed to monitor both glucose and ketones, which could help identify rising ketone levels and reduce the risk of diabetic ketoacidosis.
The cardiovascular pipeline acts as an additional growth catalyst. Abbott is preparing clinical programs for a balloon-expandable TAVR valve, a leadless conduction-system pacing device based on AVEIR, a Cephea mitral replacement valve and a peripheral IVL device, supporting the company’s growth pipeline into 2029 and beyond.
Peer Update
Thermo Fisher’s (TMO - Free Report) growth strategy remains anchored in high-impact innovation, trusted customer partnerships and its commercial engine. New launches included the Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers, the Vanquish Amplify UHPLC system and the PowerFlex Thermal Cycler.
Thermo Fisher is also expanding AI capabilities across its software portfolio and using AI within its PPI Business System to improve productivity, quality and customer responsiveness. The company is also strengthening customer collaboration through its new U.S. Bioprocess Design Center. The commercial engine supports adoption by linking new technologies with a broad customer base and integrated service offering.
Intuitive Surgical’s (ISRG - Free Report) da Vinci platform remains the core driver of its ecosystem and continues to expand through product upgrades, software and instrumentation. Intuitive continues to add digital capabilities that can improve training, workflow and hospital program management. The first phase of more than 100 da Vinci 5 updates targets telepresence, simulation-based training and care-team workflow.
Ion extends Intuitive beyond surgery into diagnostic, endoluminal procedures focused on lung biopsy. Intuitive has installed Ion in 12 countries outside the United States and continues to build clinical evidence internationally, supporting a multi-year growth path as adoption broadens.
ABT Price Performance
In the past year, Abbott shares have plunged 14.2% compared with the industry’s 24.2% decline.
Image Source: Zacks Investment Research
Expensive Valuation
ABT currently trades at a forward 12-month Price-to-Sales (P/S) of 3.69X compared with the industry’s median of 2.81X.
Image Source: Zacks Investment Research
ABT Stock Estimate Trend
In the past 30 days, ABT’s EPS estimate for 2026 has moved north 0.2%.
View the Zacks #1 Rank List
Image: Bigstock
Here's How Abbott's Medical Devices Arm Acts as a Growth Catalyst
Key Takeaways
Abbott Laboratories’ (ABT - Free Report) Medical Devices business continues to be one of the company’s strongest growth engines, supported by accelerating momentum in electrophysiology, continued adoption of cardiovascular technologies and the large long-term opportunity in continuous glucose monitoring (CGM).
Electrophysiology appears crucial to Abbott’s near-term growth acceleration. The company launched the next-generation Volt PFA catheter in the United States in May and expects to move from a limited release to a full commercial launch in the coming quarters.
Diabetes Care is another major pillar of Medical Devices growth. Abbott estimates that roughly 75-80 million people globally could realistically use CGM technology compared with only about 15 million users today. This wide penetration gap gives the company considerable runway even before factoring in future product innovation.
Abbott received CE Mark for Libre Duo in the second quarter and plans to begin its international rollout in fall 2026. Libre Duo is designed to monitor both glucose and ketones, which could help identify rising ketone levels and reduce the risk of diabetic ketoacidosis.
The cardiovascular pipeline acts as an additional growth catalyst. Abbott is preparing clinical programs for a balloon-expandable TAVR valve, a leadless conduction-system pacing device based on AVEIR, a Cephea mitral replacement valve and a peripheral IVL device, supporting the company’s growth pipeline into 2029 and beyond.
Peer Update
Thermo Fisher’s (TMO - Free Report) growth strategy remains anchored in high-impact innovation, trusted customer partnerships and its commercial engine. New launches included the Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers, the Vanquish Amplify UHPLC system and the PowerFlex Thermal Cycler.
Thermo Fisher is also expanding AI capabilities across its software portfolio and using AI within its PPI Business System to improve productivity, quality and customer responsiveness. The company is also strengthening customer collaboration through its new U.S. Bioprocess Design Center. The commercial engine supports adoption by linking new technologies with a broad customer base and integrated service offering.
Intuitive Surgical’s (ISRG - Free Report) da Vinci platform remains the core driver of its ecosystem and continues to expand through product upgrades, software and instrumentation. Intuitive continues to add digital capabilities that can improve training, workflow and hospital program management. The first phase of more than 100 da Vinci 5 updates targets telepresence, simulation-based training and care-team workflow.
Ion extends Intuitive beyond surgery into diagnostic, endoluminal procedures focused on lung biopsy. Intuitive has installed Ion in 12 countries outside the United States and continues to build clinical evidence internationally, supporting a multi-year growth path as adoption broadens.
ABT Price Performance
In the past year, Abbott shares have plunged 14.2% compared with the industry’s 24.2% decline.
Image Source: Zacks Investment Research
Expensive Valuation
ABT currently trades at a forward 12-month Price-to-Sales (P/S) of 3.69X compared with the industry’s median of 2.81X.
Image Source: Zacks Investment Research
ABT Stock Estimate Trend
In the past 30 days, ABT’s EPS estimate for 2026 has moved north 0.2%.
Image Source: Zacks Investment Research
ABT stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.